gilaxia/E+ via Getty Images
In the past 9 months Sanara MedTech (NASDAQ:SMTI) has continued to progress towards their goal of providing value based wound treatment across the continuum of care. If you missed the original writeup on SMTI’s leadership, comprehensive plan, market size, and products
Analyst’s Disclosure:I/we have a beneficial long position in the shares of SMTI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Stephen Read is the founder of HIT Investments, the general partner of HIT Capital, of which has a beneficial long positions in SMTI through stock ownership. More disclosures can be found at https://www.hitinvestments.com/disclaimer/ and within HIT Capital's Offering Documents.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
